Exenatide

What it is

Exenatide is a synthetic version of exendin-4, a peptide found in the saliva of the Gila monster. The lizard's version resembles human GLP-1 closely enough to activate the same receptor, and differs enough at the cleavage site to resist the enzyme that destroys the human hormone within minutes.

That is the entire origin of this drug class. Every compound on this site with GLP-1 in its description descends from a 1992 observation about lizard venom.

Byetta was approved in 2005, the first GLP-1 agonist anywhere. Bydureon, an extended-release weekly formulation, followed in 2012.

The withdrawal is the interesting part

AstraZeneca discontinued Bydureon BCise and Byetta in October 2024, and the FDA formally withdrew Byetta's approval in September 2025. The withdrawal notice is explicit that this was not for reasons of safety or efficacy. The product simply stopped being marketed.

This is the same distinction that matters for sermorelin, and it is worth understanding because the two situations get conflated constantly. A drug pulled for safety and a drug pulled because nobody buys it any more look identical on a list of withdrawn products, and they mean opposite things.

What happened is that exenatide was outcompeted. Twice-daily injections with more nausea and less weight loss than a weekly alternative is not a product that survives contact with semaglutide and dulaglutide. Generic exenatide is still made, so the molecule has not vanished. The brands have.

Practical notes

• Timing was tighter than with modern GLP-1 drugs. Immediate-release exenatide had to land within sixty minutes before a meal, which is a real adherence burden nobody misses.
• The extended-release form left lumps. Injection-site nodules from the microsphere formulation were common, usually harmless, and often persistent for weeks.
• It is a historical entry, not a recommendation. Exenatide appears here because it is the origin of the class and because people encounter it in older literature, not because there is a good reason to seek it out today.

Side effects and warning signs

Commonly reported

• Nausea, notably higher than with later GLP-1 drugs
• Vomiting and diarrhoea
• Injection-site nodules, particularly with the extended-release form
• Hypoglycaemia when combined with a sulfonylurea

Stop and get medical help

• Severe persistent abdominal pain radiating to the back
• Personal or family history of medullary thyroid carcinoma or MEN2, which applied to the extended-release form
• Reduced urine output or other signs of acute kidney injury, reported with volume depletion from persistent vomiting

Sources

1. Discontinuation of Bydureon BCise and Byetta, payer notice 2024regulatory
2. FDA, exenatide pediatric postmarketing pharmacovigilance reviewregulatory

From the community

Discussion for this compound concentrates in r/diabetes_t2.

No threads cached yet.

Reddit removed unauthenticated API access, so this section is populated by a build-time script using your own API credentials. Run pnpm fetch:reddit with REDDIT_CLIENT_ID and REDDIT_CLIENT_SECRET set.